by Marybeth Burke – Median progression-free survival (PFS) was significantly greater in the trametinib group, 4.8 months, vs the chemotherapy group, 1.4 months, according to a study presented
by Marybeth Burke – Wisconsin grown ginseng significantly reduced cancer related fatigue in patients receiving cancer treatment after 8 weeks of ginseng treatment,
by Marybeth Burke – Continuous hormonal therapy is more effective than intermittent hormonal therapy for men with hormone-sensitive metastatic prostate cancer with minimal disease spread,
by Marybeth Burke – Some of the most essential mainstays in cancer treatment drugs for adults and children are in short supply, Michael Link, M.D., president of the… read more.
by Marybeth Burke – The investigational drug BMS-936558 caused tumour shrinkage in up to a quarter of patients with advanced melanoma, kidney and NSCLC cancers,
by Marybeth Burke – Afatinib, an irreversible ErbB-family blocker, delays progression of advanced lung cancer in patients with epidermal growth factor receptor (EGFR) mutations compared with standard chemotherapy,
It is estimated that as many as 24 million European men aged 50 and over experience bothersome urinary symptoms.1,2 Yet, despite experiencing symptoms, men typically wait nearly two… read more.
by Bruce Sylvester – Emerging use of FDA Approved Drugs – Maraviroc, an antiretroviral drugin the treatment of HIV, significantly reduces the incidence of graft-versus-host disease (GvHD) among… read more.
The European Society for Medical Oncology (ESMO) has awarded ESMO Designated Center of Integrated Oncology and Palliative Care accreditation to 16 new oncology centres.
Men with prostate cancer in Texas may be driving more than three times farther than needed to obtain radiation oncology treatments for their cancer when treated at a… read more.
The European Society for Medical Oncology (ESMO) announced today the names of two eminent cancer specialists and one European institution that will be recognized for their contribution to… read more.
In news that is bound to excite breast cancer patients and investors, Genentech/Roche/Immunogen issued press releases on August 26, 2012, confirming that their drug-of-the-moment T-DM1 (trastuzumab emtansine) offers… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
